Know Cancer

or
forgot password

Phase II Trial of Docetaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer


Phase 2
20 Years
80 Years
Open (Enrolling)
Female
Advanced Ovarian Cancer

Thank you

Trial Information

Phase II Trial of Docetaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer


Inclusion Criteria:



- Advanced epithelial, tubal, or primary peritoneal cancer

- Cancer cells in paracentesis, thoracentesis, or laparoscopic surgery

- Less probability of complete cytoreduction

- Age: 20-80 years

- GOG performance status: 0-3

- Adequate organ function Bone marrow: ANC ≥ 1,500mm3, Platelet ≥ 100,000/mm3, Hb ≥
10.0 g/dl Kidney: Creatinine ≤ 1.25 × UNL Liver: AST, ALT ≤ × 2.5 UNL (in case of
liver metastasis, AST, ALT ≤ × 5 UNL), alkaline phosphatase ≤ 5 x UNL, bilirubin ≤
1.5 mg/ mm3

Exclusion Criteria:

- Previous chemotherapy or pelvic radiation therapy

- Final diagnosis is other malignancies

- Coincidental Other malignancies within 5 years except carcinoma in situ of uterine
cervix

- History of severe allergy

- Pregnancy, lactating woman

- Uncontrolled medial disease

- Bowel obstruction requiring immediate surgery

- Etc.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response rate

Outcome Time Frame:

1 month after completion of study treatment

Safety Issue:

No

Authority:

Korea: Institutional Review Board

Study ID:

NEODOCA-OVCA

NCT ID:

NCT01462149

Start Date:

October 2011

Completion Date:

March 2014

Related Keywords:

  • Advanced Ovarian Cancer
  • Ovarian Neoplasms

Name

Location